Los Angeles-based Cedars-Sinai Medical Center researchers developed a drug that prevents pancreatic cancer in mice, according to a study published in Gastroenterology.
Here's what you should know:
1. Researchers developed a pancreatic cancer treatment, metavert. In mice, the drug blocked drug-resistant pancreatic ductal adenocarcinomas, while boosting radiation's positive effects.
2. Metavert did not impact non-transformed cells.
3. Metavert boosted mouse survival rate, while decreasing tumor infiltration and blood levels.
In an article with Daily Science, lead study author Mouad Edderkaoui, PhD, said, "This is an exciting step toward improving survival rates in pancreatic cancer patients. If the results are confirmed in humans, we could have a drug with the potential to significantly extend the lives of patients with pancreatic ductal adenocarcinoma, which is very difficult to treat."